A single injection of our Ebola vaccine provided 100% protection for mice exposed to Ebola virus. By relying on T-cells rather than antibodies, FlowVax Ebola provides long lasting protection through enhanced immune targeting and surveillance of the hidden Ebola virus nucleocapsid protein. FLOVID-20 targets the SARS-CoV-2 virus in the same way.
FlowVax Ebola creates T-Cells that attack a specific segment of the “Nucleocapsid protein” (NP44-52) of Ebola, identified by the red arrow in the picture.
Key Features
- Under Development, FDA Approval Required.
- USA National Laboratory Study shows 100% Efficacy in C57BL/6 Mice.
- Research Paper: An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design. [PDF] [Publisher Website].
Current Status
-
PRE-CLINICAL FEASIBILITY
-
PRE-PHASE I CLINICAL STUDY
-
PHASE I
What is Ebola?
Ebola, also known as Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever of humans and other primates caused by ebolaviruses.
Colorized scanning electron micrograph of filamentous Ebola virus particles (green) attached to and budding from a chronically infected VERO E6 cell (blue) (25,000x magnification). Image captured and color-enhanced at the NIAID Integrated Research Facility in Ft. Detrick, Maryland. Credit: NIAID